Hologic to Unveil Groundbreaking AI Research at ECR 2024
27 Februar 2024 - 2:00PM
Business Wire
Global Leader in Women’s Health to Present
Research and Educational Opportunities Focused on Improving
Workflow and Efficiency
Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its
commitment to advancing women’s health by unveiling new research in
artificial intelligence (AI) and offering innovative educational
opportunities at the annual European Congress of Radiology (ECR) in
Vienna, Austria from February 28 to March 2.
The pioneer behind 3D mammography, Hologic will present new data
that showcase how next-generation deep-learning solutions can
assist with breast cancer detection and improve workflow for
radiologists. Presented by esteemed breast imaging specialist and
study author Dr. Sarah M. Friedewald, Associate Professor of
Radiology and Chief of Breast Imaging at Northwestern Memorial
Hospital, the research shows that Hologic’s Genius AI® Detection
solution has an exceptional ability to correctly match pairs of
Regions of Interest (ROIs) in different views.1
“These data reveal how AI can help us correlate ROIs in a way
that we have never seen before, which underscores that
deep-learning technology can supplement our workflow as
radiologists and help us provide better patient care,” said Dr.
Friedewald. “Beyond its impact on our daily practices, these data
emphasize the transformative potential AI has to drive improvements
across the breast health spectrum. I’m looking forward to sharing
this information with my colleagues from around the globe at
ECR.”
In addition, Dr. Friedewald will also present research
highlighting how the Genius AI Detection algorithm can help
radiologists identify potential cancers on mammograms previously
interpreted as normal.2 In a third study, research will be
presented that demonstrates Hologic’s deep learning-based AI
algorithm can help significantly enhance performance, surpassing
traditional machine learning Computer-Aided Detection (CAD)
algorithms in specificity and overall effectiveness.3
“Research and education are central tenets of Hologic’s
innovation, to support radiologists in achieving better patient
outcomes,” said Tanja Brycker, Vice President, Strategic
Development, Breast & Skeletal Health and Gynecological
Surgical Solutions at Hologic. “We’re excited to present
groundbreaking research at ECR and to continue our collaboration
with Bayer on contrast-enhanced mammography. By offering our
customers the opportunity to engage with world-renowned experts and
explore our latest technology, we are ensuring they feel confident
in their patient care procedures and decisions.”
Hologic and Bayer will co-sponsor a contrast-enhanced
mammography (CEM) symposium, facilitated by globally recognized
breast imaging radiologists Dr. Jacopo Nori, Chief of Breast
Imaging at Careggi University Hospital in Florence, Italy, and Dr.
Marc Lobbes, Chairperson of the Board, Department of Medical
Imaging at Zuyderland Medical Center in Sittard-Geleen, the
Netherlands.
The symposium, which will take place on Thursday, February 29 at
11 a.m. CET, is designed to provide radiologists with an
understanding of how CEM can be effectively implemented into their
daily practice.
Hologic’s Genius AI® Detection technology is a cutting-edge
solution now commercially available in the U.S., with plans for
rollout in Europe, Canada and Asia by the end of 2024.
About Hologic, Inc.
Hologic, Inc. is a global medical technology innovator focused
on improving the health and well-being of women, their families and
communities through early detection and treatment. Its advancements
include invention of the world’s first commercial 3D mammography
system to find breast cancer earlier; leadership in testing for
cervical cancer, sexually transmitted infections and respiratory
illnesses; and minimally invasive surgical technologies for uterine
fibroids and abnormal uterine bleeding.
The company also champions women through the Hologic Global
Women’s Health Index, which provides a science-backed data
framework for improving women’s well-being.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Hologic, The Science of Sure and Genius AI are trademarks and/or
registered trademarks of Hologic, Inc., and/or its subsidiaries in
the United States and/or other countries.
Views and opinions expressed herein by third parties are theirs
alone and do not necessarily reflect those of Hologic. Dr. Sarah M.
Friedewald is a paid Hologic consultant.
Source: Hologic, Inc.
____________________
1
Correlating breast lesions in
tomosynthesis CC and MLO views using artificial intelligence (AI).
Authors: Sarah Friedewald (Northwestern), Chirag Phargi (Solis).
Accepted as podium presentation.
2
Evaluating performance of an
artificial intelligence (AI) detection system on prior screening
tomosynthesis studies of breast cancer patients. Authors: Sarah
Friedewald (Northwestern), Chirag Phargi (Solis). Accepted as
podium presentation.
3
Performance of a traditional
machine learning computer-aided detection (CADe) algorithm versus a
deep learning artificial intelligence (AI) algorithm on digital
breast tomosynthesis (DBT) studies. Authors: Manisha Bahl (MGH),
Constance Lehman (MGH). Accepted as electronic poster.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240227246191/en/
Media Contact Bridget Perry Director, Corporate
Communications +1 508.263.8654 bridget.perry@hologic.com
Investor Contact Ryan M. Simon Vice President, Investor
Relations +1 858.410.8514 ryan.simon@hologic.com
Hologic (NASDAQ:HOLX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Hologic (NASDAQ:HOLX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024